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Abstract. Interferons have been postulated to partici- 
pate in growth regulation of normal body tissues and 
are known to inhibit growth of human epidermal ker- 
atinocytes in vitro.  Polyclonal antibodies to recom- 
binant human interferon-alpha, purified by passage 
over an affinity column (Sepharose coupled to the 
recombinant interferon), used in the indirect im- 
munofluorescent method specifically stained the 
proliferative (basal)  compartment of human epidermis 
in histological cross-sections of normal skin and in 
cultured keratinocyte colonies. Extracts prepared from 
healthy nonvirally infected keratinocyte cultures con- 
mined interferon activity as determined by viral plaque 
inhibition assay. Using the Western blotting technique 
column-purified antibodies and antisera to recombinant 
human interferon-alpha recognized a band of ~40 kD 
when reacted with both extracted keratinocyte proteins 
and recombinant human interferon-alpha standards, 
that gave in addition a band of ~20 kD.  The above 
findings suggest that interferon or a closely related 
protein is present in the proliferative compartment of 
normal epidermis in the absence of viral infection and 
therefore may serve as a physiological modulator of 
epidermal growth. 
I 
NTEI~rEI~ONS (IFNs) ~ are  a  family  of  glycoproteins 
presently classified as alpha, beta, or gamma on the ba- 
sis  of  biological  and  physiochemical  characteristics 
(42).  IFNs were first identified by their anti-viral activity 
during studies of viral interference (21), but have since been 
widely recognized to inhibit proliferation of  both normal and 
malignant ceils in vitro (4, 17, 19) and are under investigation 
as anti-tumor drugs in several clinical trials (2).  We have 
previously demonstrated that cultured human keratinocytes 
produce IFN of an unknown type in response to herpes virus 
infection in vitro (35).  We and others have shown that addi- 
tion of either IFN-alpha or IFN-beta to human keratinocytes 
in vitro profoundly and reversibly inhibits cell growth (28, 
47) and increases terminal differentiation, as determined by 
the percentage of cells with cornified envelopes and by the 
detachment rate for cells from the colony surface (47). 
It is known that human lymphoblastoid cell lines can liber- 
ate IFN in small quantity in the absence of overt stimulation 
(32) and that there are substantial antigenic differences be- 
tween the spontaneously produced IFN and the virally in- 
duced IFN (7).  Recently, Moore and co-workers reported 
that bone marrow stem cells produce IFN when stimulated 
by a specific growth factor known as colony-stimulating fac- 
tor 1 or macrophage growth factor, and that the cellular re- 
sponse to this growth factor is further augmented if cultures 
are treated with anti-IFN antibodies (27).  These combined 
findings suggest that IFN may function as a physiological 
regulator of cell growth in vivo with properties of a negative 
growth factor or chalone (20). 
We now report that IFN or a closely related protein is pres- 
1. Abbreviation  used in this paper:  IFN,  interferon. 
ent in the proliferative compartment of normal epidermis in 
the absence of viral infection and suggest that this protein 
may represent a  physiological growth inhibitor in human 
skin.  This protein binds polyclonal antibodies to recom- 
binant human IFN-alpha that have been purified by passage 
over an affinity column (Sepharose coupled to the recom- 
binant interferon). The binding is localized in the prolifera- 
tive (basal) compartment of human epidermis in histological 
cross-sections of normal skin and in cultured keratinocyte 
colonies. Extracts prepared from healthy nonvirally infected 
keratinocyte cultures contain IFN activity as determined by 
viral cytopathic inhibition assay. Column purified antibodies 
and antisera to recombinant human IFN-alpha recognize a 
band of •40  kD when reacted with both extracted keratino- 
cyte proteins and recombinant human IFN-alpha standards, 
that give in addition a band of ~,20 kD. 
Materials and Methods 
llssues and Cell Culture 
Newborn foreskins or cutaneous biopsies of healthy adult volunteers were 
embedded and frozen in tissue Tek II O.C.T, (Lab Tek Products, Naperville, 
IL).  Primary keratinocyte (10) and fibroblast (12) cultures were prepared 
from newborn foreskins as described. At confluence dishes were washed 
twice with 0.02% EDTA, incubated in 0.25% trypsin at 37°C, and disag- 
gregated to form a single cell suspension. Keratinocytes or fibroblasts were 
inoculated either on glass coverslips or (keratinocytes 0nly) on dishes coated 
with human fibronecfin 10 Ixg/em  2 (11). Cultures were maintained at 37°C 
in 8% CO2 and provided three times weekly with serum-free medium 199 
supplemented with 10 ~tg/ml insulin (Sigma Chemical Co., St. Louis, MO), 
10  ng/ml  epidermal  growth  factor  (Bethesda  Research  Laboratories, 
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transferrin  (Sigma  Chemical  Co.),  1.4  x  10  4  M  hydrocortisone 
(Calbiochem-Behring Corp., La Jolla, CA), 2 mg/ml bovine serum albumin 
(Sigma Chemical Co.), and 150 lxg/ml crude bovine hypothalamic extract 
(25).  At confluence cells on coverslips were fixed with acetone at  -20°C 
for 30 s (40) and used for indirect immunofiuorescence.  Confluent keratino- 
cyte sheets were detached from dishes with medium containing 1.2 ~tg/ml 
Dispase II  (Boehringer Mannheim Biochemicals, Indianapolis, IN)  (16), 
then embedded and frozen in Tissue Tek II O.C.T. and processed for indirect 
immunofluorescence. 
Antibodies 
Polyclonal antibodies to recombinant human IFN-alpha were prepared by 
subacutaneous  injections of New Zealand white rabbits at four different sites 
with a total of I mg of recombinant human IFN-alpha (monomer form) in 
Freund's complete adjuvant. The animals were given booster injections of 
500 p.g in incomplete Freund's adjuvant weekly for a total of 4  wk.  1 wk 
after the fourth injection, blood was obtained from each rabbit. The animals 
were bled before immunization and their pre- and postimmunization serum 
samples were screened for the presence of antibodies to recombinant human 
IFN-alpha by Ouchterlony agarose double diffusion analysis and antibody 
neutralizing bioassay (34).  Antibodies (0.48-1.26  ×  106 interferon neu- 
tralizing units/ml) were detected in the immune sera only. 
Monoclonal antibodies to recombinant human IFN-alpha were prepared 
as described  (38).  Briefly,  female BALB/c mice (Jackson  Laboratories) 
were inoculatexl with 5-10  ×  106 hybridoma cells from mid log growth 
phase. The ascitic fluid from each mouse was collected repeatedly and tested 
for specific antibody activity by a solid phase antibody binding assay (39). 
Proteins from ascitic fluids with high levels of antibodies were precipitated 
with saturated ammonium sulfate solution, then dissolved in 0.02 M  Tris 
HCI  with 0.04  M  NaCl and applied over a  column of DEAE-cellulose 
(DE52,  Whatman Inc., Clifton,  NJ).  The antibody was eluted from the 
column with a linear NaCI gradient from 0.04 to 0.5 M NaCI. Pooled peak 
fractions elnting between 0.6 and 0.1 M NaCI were concentrated with satu- 
rated  ammonium sulfate and  dissolved in 0.2  M  NaHCO3  with 0.3  M 
NaCI. The eluants were screened for the presence of antibodies to recom- 
binant human IFN-alpha by antibody neutralization bioassay (34). Antibody 
titers were  1.7-5.1  x  106 interferon neutralizing units/mg protein. 
Purification of  Anti-recombinant  Human IFN-Alpha 
Antibodies from Rabbit Sera 
Purification of anti-recombinant human IFN-alpha antibodies from two rab- 
bit sera was obtained by conventional affinity chromatography (36) using a 
column of Sepharose 4B coupled to recombinant human IFN-alpha.  The 
column was prepared using 5 mg of pure recombinant human IFN-alpha dis- 
solved in and displayed against 0.1  M  NaHCO3 buffer pH 8.3 containing 
0.5  M  NaCI.  The  IFN  solution was added to  0.5  g  of CNBr-activated 
Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ) and the coup- 
ling was carried out according to manufacturer's recommendations. Either 
IFN-alpha antiserum or preimmune serum (0.3-0.7 ml) was added to the 
column. The column was washed with 7 column vol of phosphate-buffered 
saline. The specifically bound antibody was then eluted with 0.5 N acetic 
acid containing 0.5 M NaCI followed by 0.5 N HCI containing 0.5 M NaC1. 
Pooled peak fractions were concentered by ultrafiltration on a YM10 Ami- 
con filter (Amicon Corp., Danvers, MA) and used for immunofluorescence 
and immunoblotting. 
Immunofluorescence 
6-tam sections of fresh frozen tissues or cells were incubated with immune 
rabbit  serum, preimmune rabbit serum, column-purified antibodies from 
immune serum, column-purified antibodies from preimmune serum, or 
monoclonal antibodies. The second antibody used was ffuorescein-tagged 
goat anti-rabbit  IgG or goat anti-mouse IgG  (CooperBiomedical,  Inc., 
Malvern, PA) (9). 
lmmunoblotting 
Confluent keratinocyte cultures were prepared in a small volume of 0.5 % 
Nonidet P-40 in Tris-buffered saline containing 1 mM phenylmethylsulfonyl 
fluoride (41).  The extracted proteins and pure recombinant human IFN- 
alpha (2.5 I.tg  of a standard preparation) were reduced and separated by 12% 
SDS  PAGE,  then electrophoretically  transferred  to  nitrocellulose  paper 
using a Bio-Rad transblot apparatus (Bio-Rad Laboratories, Richmond, CA) 
overnight at 4°C, 60 V in Tris-glycine buffer with 20% methanol (41). Anti- 
gens on  the nitrocellulose paper  were  incubated  with  either  IFN-alpha 
antiserum or preimmune serum at  1:250-1:500 dilution, column-purified 
IFN-alpha antiserum, or column-purified preimmune serum at 1:50-1:250 
dilution, and monoclonal antibodies to IFN-alpha at 1:50-1:500 dilution. 
Specific binding of antibodies was identified by immunoperoxidase staining 
of the nitrocellulose paper strips. 
IFN Activity of  Keratinocyte Extracts 
Interferon activity of keratinocyte extracts was determined quantitatively by 
reduction of cytopathic effect of vesicular stomatitis virus using a bovine 
kidney cell line of epithelial origin (34). The extract samples used to mea- 
sure interferon activity were serially diluted and added to infected cells ei- 
ther immediately after viral inoculation or 24 h  later.  Cultures were in- 
cubated at 37°C until the virally infected control cells displayed a  100% 
cytopathic effect. The IFN titer was then read as the reciprocal of the extract 
dilution that protected 50% of the cell monolayer. A laboratory standard of 
IFN was included in all assays. 
Results 
Antibody Binding 
Two sera obtained from rabbits immunized against recom- 
binant human IFN-alpha produced staining of the epidermal 
basal layer in tissue cross-sections with occasional staining 
in the first few suprabasilar layers (Fig.  1 a), while control 
specimens incubated with preimmune serum were negative 
(Fig. 1 b). Three monoclonal antibodies to recombinant hu- 
man IFN-alpha  gave negative staining  when reacted with 
cross-sections of normal skin. 
To determine whether the IFN staining was retained in cul- 
tured epidermis,  second passage  human keratinocyte cul- 
tures grown under serum-free conditions (25)  were either 
detached from the dish by the use of Dispase II (16) and fro- 
zen or grown on coverslips and fixed in  -20°C acetone for 
30 s  (40).  Immunofluorescent staining  was present in the 
basal layer of stratified colonies in a pattern analogous to that 
observed in vivo (Fig. 2 a), and individual cells displayed 
bright cytoplasmic fluorescence (Fig. 2 b). Stratified colo- 
nies incubated with preimmune serum were negative (Fig. 2 
c and d). Cultured epidermis inoculated with the monoclo- 
nal antibodies failed to stain.  Since both human and rabbit 
sera  may contain  antibodies  to  keratin  proteins  (22),  we 
repeated these studies using cultures of rapidly proliferating 
human dermal fibroblasts.  Fibroblasts incubated with im- 
mune sera also displayed bright fluorescence, suggesting but 
not proving that the staining pattern observed in the keratino- 
cytes was  not due to keratin. 
To further exclude the possibility that the staining pattern 
was due to antibodies nonspecifically induced during the im- 
munization procedure, the reactive rabbit anti-sera were ap- 
plied to an IFN affinity column of Sepharose 4B coupled to 
recombinant human IFN-alpha (36).  Material eluted from 
the IFN affinity column (specifically bound) and material in 
the column washes (nonbound) were separately concentrated 
and used in the above procedure. Skin sections reacted with 
the purified antibodies present in the concentrated eluant re- 
vealed the same fluorescent staining pattern observed with 
whole sera (Fig.  1 c),  while the comparably concentrated 
washes gave no staining whatsoever (Fig.  1 d).  Similarly, 
cultured epidermis reacted with the purified antibodies pres- 
ent in the concentrated eluant revealed the same fluorescent 
The Journal of Cell Biology, Volume  103, 1986  1350 Figure 1. Binding of anti-IFN antiserum  (a) and column-purified anti-IFN antibodies (c) to normal human skin. Bright fluorescence is 
present in the basal layer of the epidermis. The remainder of the viable epidermis and the stratum corneum are negative. Faint nonspecific 
linear fluorescence is frequently present in both these sections and control sections within the stratum granulosum (b and d). Representative 
sections from one of two sera and one of eight tissue donors are shown. Bar, 20 lam. 
staining pattern observed with whole sera (Fig. 2 e and f), 
while  the  comparably concentrated  washes  again gave no 
staining. 
Interferon Activity in Keratinocyte  Cell Extracts 
To determine whether the positive staining pattern was as- 
sociated with the presence of biologically active IFN, cell 
extracts and conditioned medium from confluent keratino- 
cyte cell cultures,  nonconditioned  medium, and extracting 
solution alone prepared as described (40) were analyzed for 
IFN activity in a cytopathic effect assay that could detect as 
little as  2  interferon  neutralizing  units/ml  of IFN activity 
(34). IFN activity was found exclusively in the cell extracts 
and  was  titered  to  38  interferon  neutralizing  units/ml  in 
triplicate samples, ",,0.4 % of the peak values measured pre- 
viously by a different methodology in the medium of com- 
parably confluent keratinocyte cultures infected with herpes 
simplex virus (35). 
Characteristics  of  Interferon Present in 
Cultured Keratinocytes 
To determine the molecular weight of IFN present in cul- 
tured  keratinocytes,  confluent  cultures  were  extracted  as 
above, the proteins separated by SDS PAGE and transferred 
Yaar et al. Interferon in Normal Human Epidermis  1351 Figure 2.  Binding  of anti-IFN antiserum to stratified  keratinocyte  cultures.  Antibodies from immune serum (a) and column-purified 
anti-IFN antibodies  (e) bound to the basal cell  layer (BCL) of cultured keratinocyte  colonies sectioned  vertically  and displayed  bright 
cytoplasmic fluorescence in the respective  en face preparations  (b and f).  Antibodies  from preimmune serum did not bind to vertically 
sectioned keratinocytes  colonies (c) or to keratinocytes  grown on coverslips  (d).  Bar,  5  ~tm. 
to nitrocellulose paper (46), and the lanes reacted separately 
with either immune sera, column-purified anti-IFN antibod- 
ies from these sera,  appropriate control sera,  column-puri- 
fied  preimmune  sera,  or  monoclonal  antibodies  to  IFN. 
Antigen binding  on nitrocellulose  paper  was  identified  by 
immunoperoxidase  staining  (41).  Immune  sera  and  the 
affinity column-adherent antibodies from these sera bound 
principally  to  an  •20-kD  recombinant human  IFN-alpha 
standard and, to a lesser degree, to its ~40-kD dimer (Fig. 
3), as expected (31).  Monoclonal antibodies bound to these 
bands as well (data not shown). In lanes containing cell ex- 
tracts, antibodies derived from immune sera recognized only 
a  protein of ~40 kD.  Preimmune sera and affinity column 
eluants  prepared  from  these  sera  did  not  bind  either  to 
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IFN  antibody  binding  to  keratinocyte 
cell  extracts. Antibodies  used  are  ei- 
ther rabbit serum containing antibodies 
against recombinant human IFN-alpha 
(lane 1) or column-purified antibodies 
from immune rabbit serum (lanes 3 and 
5). One of three positive sera is shown 
in this immunoblot (numbers on right 
indicate kilodaltons).  A  ~40-kD band 
is  recognized  by  immune  serum  and 
purified  antibodies  but not by preim- 
mune serum (lane 2) or column-purified 
antibodies from preimmune sera (lanes 
4  and  6).  Column-purified antibodies 
that recognize the ,~40-kD band (lanes 
1,  3,  and 5) also bind to the  ~20-kD 
band of pure recombinant human IFN- 
alpha and to its dimer at ,~40 kD (lanes 
7 and 8).  Molecular  weight standards 
are shown in lane 9. 
recombinant human IFN-alpha or to the 0o40-kD protein in 
the cell extract (Fig. 3). The monoclonal antibodies did not 
bind to the cell extracts. 
Discussion 
We have shown that a  protein cross-reacting with recom- 
binant human IFN-alpha is present in the proliferative com- 
partment of normal human epidermis in vivo and in vitro in 
the absence of viral infection and that extracts of cultured 
keratinocytes contain IFN-like anti-viral activity. The use of 
multiple newborn and adult skin donors effectively elimi- 
nates the possibility that clinically undetectable viral infec- 
tion was responsible for these findings. The precise nature 
of  the  IFN-like  substance  in  the  basal  layer  of human 
epidermis remains unclear, however. Failure of three differ- 
ent anti-IFN-alpha monoclonal antibodies to bind this pro- 
tein argues against  its identity with this  class  of IFN,  al- 
though  masking  of  multiple  antige~  sites  within  the 
keratinocytes, remains  a  possibility. ~larly,  if the sub- 
stance is indeed IFN-alpha, the absence of its usually pre- 
dominant 0o20-kD species must be explained, even though 
dimers of recombinant human  IFN-alpha  of 0o40 kD  are 
known to exist in vivo and in vitro and to persist under reduc- 
ing conditions as in SDS PAGE (31). Present data do not al- 
low us to distinguish between a modified monomeric form 
of IFN-alpha, a persistent dimer of the otherwise predomi- 
nant monomer, and a previously unrecognized class of  IFNs. 
The epidermis constantly renews itself. In normal skin, 
however, the majority of the cells in the germinative basal 
layer compartment are blocked either in G1, G2, or Go and 
do not cycle unless stimulated (18). The precise controls for 
epidermal cell proliferation in vivo are virtually unknown, 
although circumstances such as wounding, ultraviolet irradi- 
ation,  certain disease states,  and chronological aging have 
undeniable influences (1,  13). Substances reported to influ- 
ence epidermal population dynamics in vitro include epider- 
mal growth factor (33), calcium (3), cyclic nucleotides (15), 
prostaglandins (44), vitamin A (6, 37), and various tissue ex- 
tracts (14, 29, 30), but their physiological roles in normal or 
diseased skin are speculative. The present data suggest that 
IFNs may have a  physiological or therapeutic role in dis- 
orders such as psoriasis (8) that are characterized by revers- 
ible epidermal hyperplasia, accelerated epidermal turnover 
rate, and compromised keratinocyte differentiation. 
Chalones were first conceptualized by Bullough in 1962 as 
tissue specific, species nonspecific substances that can in- 
hibit cell division (5). Although tentatively identified in the 
epidermis (5, 26) and avidly investigated over many years, 
chalones have proven elusive (24, 26). Although IFNs do not 
satisfy all the original criteria for epidermal chalones (5), 
their demonstrated ability to inhibit growth of cultured ker- 
atinocyte profoundly and reversibly (28, 47) make them ex- 
cellent candidates for assuming such a function in vivo. IFN- 
alpha is known to behave as a negative feedback inhibitor for 
bone marrow cells at least in vitro (27), and the presence of 
IFN in the amniotic fluid of pregnant women during the sec- 
ond and third trimesters in the absence of detectable viral in- 
fection (23) suggests that IFN may participate in the regula- 
tion of fetal development. The present report demonstrates 
that  an  IFN-like  protein  is  constitutively present  in  the 
proliferative layer of the epidermis. Intuitively, one might ex- 
pect a chalone to be present in the suprabasilar nonprolifera- 
tive compartment of the epidermis. However, the existence 
of such a regulatory factor in the basal layer, within poten- 
tially dividing cells that under normal conditions are never- 
theless  noncycling,  is  also plausible.  We  suggest that the 
IFN-like protein observed in  these  studies  may therefore 
serve as a chalone in this precisely regulated tissue. 
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